Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Affiliations

• ¹ Cardiovascular Division, Brigham & Women's Hospital and Baim Institute for Clinical Research, Boston, MA (C.P.C.).
• ² The George Institute for Global Health, UNSW Sydney, Australia (V.P., H.J.L.H, M.J.J., J.-W.L., B.N.).
• ³ The Royal North Shore Hospital, Sydney, Australia (V.P.).
• ⁴ Indiana University School of Medicine and VA Medical Center, Indianapolis (R.A.).
• ⁵ Janssen Research & Development, LLC, Raritan, NJ (J.B., R.E.).
• ⁶ Department of Medicine, University of Chicago Medicine, IL (G.B.).
• ⁷ Nephrology Division, NYU School of Medicine and NYU Langone Medical Center (D.M.C.).
• ⁸ Baim Institute for Clinical Research, Boston, MA (D.M.C.).
• ⁹ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands (D.d.Z., H.J.L.H.).
• ¹⁰ Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City (T.G.).
• ¹¹ Concord Repatriation General Hospital, Sydney, Australia (M.J.J.).
• ¹² Division of Nephrology, University of British Columbia, Vancouver, Canada (A.L.).
• ¹³ The Charles Perkins Centre, University of Sydney, Australia (B.N.).
• ¹⁴ Imperial College London, United Kingdom (B.N.).
• ¹⁵ Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia (C.P.).
• ¹⁶ Department of Renal Medicine, UCL Medical School, London, United Kingdom (D.C.W.).
• ¹⁷ Renal Division of Peking University First Hospital, Beijing, China (H.Z.).
• ¹⁸ Lunenfeld-Tanenbaum Research Institute, Mt Sinai Hospital, University of Toronto, Ontario, Canada (B.Z.).
• ¹⁹ Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (K.W.M.).